Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02266355 · ClinicalTrials.gov registry record · Phase 1
Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02266355 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 9 participants.
The verdict
NCT02266355, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Pilot study to evaluate the activity of omalizumab in the prevention of recurrent oxaliplatin hypersensitivity reaction (HSR) in oxaliplatin-sensitive patients. The study will also evaluate the safety of omalizumab (Xolair) when administered in this setting.
Interventions
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02266355
The ClinicalTrials.gov registry entry for NCT02266355 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omalizumab is the first listed.
NCT02266355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02266355 about?
NCT02266355 is a clinical study titled "Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction". Pilot study to evaluate the activity of omalizumab in the prevention of recurrent oxaliplatin hypersensitivity reaction (HSR) in oxaliplatin-sensitive patients. The study will also evaluate the safety of omalizumab (Xolair) when administered in this setting.
What is the current status of trial NCT02266355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2014-11. Estimated completion is 2018-02-27.
What interventions are being tested in trial NCT02266355?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT02266355?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.